Notis McConarty Edward Takes $306,000 Position in Novo Nordisk A/S (NYSE:NVO)

Notis McConarty Edward purchased a new stake in Novo Nordisk A/S (NYSE:NVO - Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 4,410 shares of the company's stock, valued at approximately $306,000.

A number of other hedge funds have also recently bought and sold shares of the stock. Strategic Investment Solutions Inc. IL lifted its holdings in shares of Novo Nordisk A/S by 2,727.3% during the 4th quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company's stock worth $27,000 after acquiring an additional 300 shares during the period. Copeland Capital Management LLC lifted its holdings in shares of Novo Nordisk A/S by 184.8% during the 1st quarter. Copeland Capital Management LLC now owns 393 shares of the company's stock worth $27,000 after acquiring an additional 255 shares during the period. North Capital Inc. bought a new position in shares of Novo Nordisk A/S during the 1st quarter worth about $27,000. Park Square Financial Group LLC bought a new position in shares of Novo Nordisk A/S during the 4th quarter worth about $29,000. Finally, Transce3nd LLC bought a new position in shares of Novo Nordisk A/S during the 4th quarter worth about $33,000. 11.54% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. Dbs Bank downgraded shares of Novo Nordisk A/S to a "sell" rating in a report on Friday, April 25th. BNP Paribas began coverage on shares of Novo Nordisk A/S in a research report on Tuesday, April 15th. They set an "underperform" rating for the company. BMO Capital Markets reissued a "market perform" rating and set a $64.00 price objective (down previously from $105.00) on shares of Novo Nordisk A/S in a research note on Thursday, April 17th. Wall Street Zen raised shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research note on Saturday, June 14th. Finally, Guggenheim lowered shares of Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research report on Thursday, April 17th. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating, four have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Novo Nordisk A/S has a consensus rating of "Hold" and an average price target of $112.00.

Novo Nordisk A/S Price Performance

Novo Nordisk A/S stock traded up $0.94 during trading hours on Friday, reaching $71.67. 7,345,265 shares of the stock were exchanged, compared to its average volume of 7,144,964. The company has a market cap of $320.00 billion, a P/E ratio of 21.20, a price-to-earnings-growth ratio of 1.36 and a beta of 0.64. The company has a current ratio of 0.74, a quick ratio of 0.56 and a debt-to-equity ratio of 0.70. Novo Nordisk A/S has a twelve month low of $57.00 and a twelve month high of $139.74. The stock has a 50 day moving average of $70.67 and a two-hundred day moving average of $73.80.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported $0.92 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.92. The firm had revenue of $11.87 billion for the quarter. Novo Nordisk A/S had a net margin of 34.52% and a return on equity of 80.94%. Equities analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.